<style> .wpb_animate_when_almost_visible { opacity: 1; }</style>


HLS Therapeutics is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. We focus on products targeting the central nervous system and cardiovascular therapeutic areas. Our management team is comprised of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. HLS Therapeutics listed publicly on the TSXV in March 2018 by way of a reverse takeover of Automodular Corporation. On February 7, 2019, HLS Therapeutics graduated from the TSXV and its shares began trading on the TSX exchange.

Thursday, August 12, 2021
11:00am EDT

View All


The information contained on the Investor Relations section of this website was accurate at the time of posting, but may be superseded by subsequent disclosures. Please check the date of the material posted.

Aug 16, 2021

Agreement enables rapid, efficient and impactful expansion to the primary care physician audience. HLS will continue to focus primarily on specialists while Pfizer will focus primarily on primary...

Aug 5, 2021

Q2 2021 revenue of $14.9 million and Adjusted EBITDA of $6.6 million, up 19% and 36%, respectively, from Q2 2020 Generated strong Vascepa® prescription growth - amid persistent COVID-19...

Aug 4, 2021

HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim...

Read More